受体酪氨酸激酶融合与BRAF融合是EGFR-TKI罕见但可靶向的耐药机制
该研究分析了3505例EGFR突变NSCLC临床样本,鉴定出31例合并激酶融合(BRAF、ALK、RET、FGFR3、EGFR、NTRK1),其中12例配对前样本无融合。多例靶向EGFR与融合的双重治疗获临床获益,提示融合检测应纳入耐药评估以指导联合策略。
要点
- EGFR突变NSCLC中激酶融合罕见但可靶向,应纳入耐药检测。
- 获得性融合(如PLEKHA7-ALK)可致奥希替尼耐药,联合治疗有效。
- 融合阳性患者多既往接受过EGFR-TKI,配对样本证实融合为获得性。
核心结论
- RTK和BRAF融合是EGFR-TKI罕见但可靶向的耐药机制。
- 融合检测应纳入全面 profiling 以指导联合治疗策略。
研究设计与样本
- 回顾性分析3505例EGFR突变NSCLC临床样本(FFPE肿瘤和血液),检测RTK和BRAF融合,从病理报告和临床医生获取治疗史和反应。
主要发现
- 31例EGFR突变NSCLC检出并发激酶融合:BRAF 10例(32%),ALK 7例(23%),RET 6例(19%),FGFR3 6例(19%),EGFR 1例(3.2%),NTRK1 1例(3.2%),包括两个新融合(SALL2-BRAF和PLEKHA7-ALK)。
- 31例中27例在融合阳性样本收集前有EGFR突变NSCLC诊断史或既往EGFR-TKI治疗史。
- 27例中12例有配对治疗前样本,治疗前未检出融合。
- 多例接受靶向EGFR和获得性融合的联合治疗获临床获益,包括1例奥希替尼耐药因获得性PLEKHA7-ALK融合,经全剂量奥希替尼联合阿来替尼获持久部分缓解。
临床怎么用
- 对EGFR-TKI耐药患者应进行包含RTK和BRAF融合的全面检测。
- 检出可靶向融合后,可考虑EGFR-TKI联合相应融合抑制剂的治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: We analyzed a large set of EGFR-mutated (EGFR+) NSCLC to identify and characterize cases with co-occurring kinase fusions as potential resistance mechanisms to EGFR tyrosine kinase inhibitors (TKIs). METHODS: EGFR+ (del 19, L858R, G719X, S768I, L851Q) NSCLC clinical samples (formalin-fixed paraffin-embedded tumor and blood) were analyzed for the presence of receptor tyrosine kinase (RTK) and BRAF fusions. Treatment history and response were obtained from provided pathology reports and treating clinicians. RESULTS: Clinical samples from 3505 unique EGFR+ NSCLCs were identified from June 2012 to October 2017. A total of 31 EGFR+ cases had concurrent kinase fusions detected: 10 (32%) BRAF, 7 (23%) ALK receptor tyrosine kinase (ALK), 6 (19%) ret proto-oncogene (RET), 6 (19%) fibroblast growth factor receptor 3 (FGFR3), 1 (3.2%) EGFR, and 1 (3.2%) neurotrophic receptor tyrosine kinase 1 (NTRK1), including two novel fusions (SALL2-BRAF and PLEKHA7-ALK). Twenty-seven of 31 patients had either a known history of EGFR+ NSCLC diagnosis or prior treatment with an EGFR TKI before the fusion+ sample was collected. Twelve of the 27 patients had paired pre-treatment samples where the fusion was not present before treatment with an EGFR TKI. Multiple patients treated with combination therapy targeting EGFR and the acquired fusion had clinical benefit, including one patient with osimertinib resistance due to an acquired PLEKHA7-ALK fusion achieving a durable partial response with combination of full-dose osimertinib and alectinib. CONCLUSIONS: RTK and BRAF fusions are rare but potentially druggable resistance mechanisms to EGFR TKIs. Detection of RTK and BRAF fusions should be part of comprehensive profiling panels to determine resistance to EGFR TKIs and direct appropriate combination therapeutic strategies.
引用
- Schrock AB, Zhu VW, Hsieh WS, et al. Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors. J Thorac Oncol. 2018. PMID: 29883838. doi:10.1016/j.jtho.2018.05.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。